Our Business

Phosphagenics Limited is a Melbourne-based biotechnology company which has developed a unique delivery technology based on tocopherol phosphate (Vitamin E phosphate).  This platform technology, known as TPM® is able to deliver actives and drugs into or through the skin.

Phosphagenics shares are listed on the Australian Securities Exchange (ASX: POH).  Phosphagenics ADR’s are also traded on the OTCQX in the USA.





 

Breaking News


23 April 2014

PHOSPHAGENICS COMPLETES ENROLMENT IN PHASE 2 ACNE TREATMENT TRIAL

Phosphagenics today announced that it has completed enrolment for its Phase 2 clinical trial of the Company's improved treatment for the common skin disorder acne vulgaris.

View our latest news releases/presentations/newsletters:


3 April 2014

PHOSPHAGENICS INVESTOR WEBCAST PRESENTATION

If you wish to listen to the webcast held, register here:
 http://public.viavid.com/player/index.php?id=108450



17 March 2014

PHOSPHAGENICS NEWSLETTER MARCH 2014


3 March 2014

PHOSPHAGENICS APPOINTS THREE NEW NON-EXECUTIVE DIRECTORS

Phosphagenics has appointed biotech industry veterans Mr Lawrence Gozlan, Mr Nathan Drona and Dr Geert Cauwenbergh as non-executive directors, with Mr Gozlan assuming the role of Chairman of the Board on an interim basis. 

Mr Stuart James, Dr Sandra Webb, Mr Don Clarke and Mr Jonathan Addison have retired from the Board. The Company thanks them for their contributions over many years.